Wegovy and Zepbound prices are dropping, but steady access to the weight-loss drugs remains a challenge
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even for people with insurance, coverage remains uneven. “The medications should be available, the question is at […]
Optimal Data Sources for Studies of Incident Dementia
In JAMA Internal Medicine, Luchsinger et al describe the results of a prespecified secondary analysis of the GRADE clinical trial on cognitive performance. The GRADE trial randomized 3721 patients with type 2 diabetes using metformin at baseline to add either a long-acting insulin, a sulfonylurea, a glucagon-like peptide-1 (GLP-1) agonist, or a dipeptidyl peptidase-4 inhibitor. […]
H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3
Opko Health Inc. (NASDAQ:OPK) is one of the 13 Stocks Under $5 With High Upside Potential. On May 1, analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Opko Health Inc. (NASDAQ:OPK), retaining the price target of $3.00. Despite mixed fiscal Q1 2025 results, the rating was supported by future prospects and strategic […]